SAB Biotherapeutics Announces Appointment of Erick Lucera CFA to Board of Directors SAB Biotherapeutics NASDAQSABSW SAB Biotherapeutics NASDAQSABS

SIOUX FALLS, S.D., April 04, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics SABS, (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB’s Board of Directors, effective April 4, 2023. Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 2020…